WBIO.CN Stock - WPD Pharmaceuticals Inc.
Unlock GoAI Insights for WBIO.CN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | $-24,436 | $-290,218 | $-391,770 | $-111.095 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-268,910 | $-2,329,220 | $-6,331,760 | $-8,458,470 | $-12,073,775 |
| Net Income | $-80,082 | $3.86M | $-5,623,150 | $-7,522,701 | $-12,776,341 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.00 | $0.03 | $-0.05 | $-0.07 | $-0.18 |
WPD Pharmaceuticals Inc. engages in the research and development of medicinal products in the fields of oncology and infectious diseases. Its drug development pipeline includes WPD101 to treat brain cancers, including glioblastoma that is in the pre-clinical trial; WPD102 to treat Uval Melanoma, which is in the pre-clinical trial; Berubicin for the treatment of glioblastoma that us in phase 1 clinical trial; and WP1066 to treat central nervous system tumors, pancreatic cancer, and ocular tumors, which is in phase 1 clinical trial. The company's drug development pipeline also includes WP1732 for the treatment of pancreatic cancer; WP1220 to treat cutaneous T-cell lymphoma; WPD103 for the treatment of glioblastoma multiforme that is in the pre-clinical trial; and Annamycin to treat acute myeloid leukemia (AML) and metastasis to lungs, which is in Phase I/II clinical trials in AML. WPD Pharmaceuticals Inc. is headquartered in Vancouver, Canada.
Visit WebsiteEarnings History & Surprises
WBIO.CNEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2024 | Sep 30, 2024 | — | $0.00 | — | — |
Q2 2024 | Jun 29, 2024 | — | $-0.00 | — | — |
Q1 2024 | Mar 30, 2024 | — | $-0.00 | — | — |
Q1 2024 | Feb 2, 2024 | — | $0.00 | — | — |
Q1 2024 | Jan 30, 2024 | — | $-0.00 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.00 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-0.00 | — | — |
Q1 2023 | Mar 13, 2023 | — | $-0.01 | — | — |
Q4 2022 | Dec 31, 2022 | — | $0.05 | — | — |
Q2 2022 | Jun 29, 2022 | — | $-0.01 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-0.01 | — | — |
Q4 2021 | Dec 30, 2021 | — | $-0.02 | — | — |
Q4 2021 | Nov 29, 2021 | — | $-0.01 | — | — |
Q3 2021 | Sep 30, 2021 | — | $-0.01 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-0.01 | — | — |
Q4 2020 | Dec 31, 2020 | — | $-0.02 | — | — |
Q3 2020 | Sep 30, 2020 | — | $-0.01 | — | — |
Q2 2020 | Jun 30, 2020 | — | $-0.02 | — | — |
Q1 2020 | Mar 31, 2020 | — | $-0.02 | — | — |
Q4 2019 | Dec 31, 2019 | — | $-0.09 | — | — |
Latest News
Frequently Asked Questions about WBIO.CN
What is WBIO.CN's current stock price?
What is the analyst price target for WBIO.CN?
What sector is WPD Pharmaceuticals Inc. in?
What is WBIO.CN's market cap?
Does WBIO.CN pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to WBIO.CN for comparison